JP2018522860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522860A5 JP2018522860A5 JP2017566712A JP2017566712A JP2018522860A5 JP 2018522860 A5 JP2018522860 A5 JP 2018522860A5 JP 2017566712 A JP2017566712 A JP 2017566712A JP 2017566712 A JP2017566712 A JP 2017566712A JP 2018522860 A5 JP2018522860 A5 JP 2018522860A5
- Authority
- JP
- Japan
- Prior art keywords
- metal organic
- organic structure
- amorphous
- component
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005300 metallic glass Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 229910052751 metal Inorganic materials 0.000 claims 16
- 239000002184 metal Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000013543 active substance Substances 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000013207 UiO-66 Substances 0.000 claims 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
- 229910052726 zirconium Inorganic materials 0.000 claims 2
- 238000005280 amorphization Methods 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 238000000498 ball milling Methods 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1511125.5A GB201511125D0 (en) | 2015-06-24 | 2015-06-24 | Amorhous metal-organic frameworks |
| GB1511125.5 | 2015-06-24 | ||
| PCT/EP2016/064746 WO2016207397A1 (en) | 2015-06-24 | 2016-06-24 | Amorphous metal-organic frameworks |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522860A JP2018522860A (ja) | 2018-08-16 |
| JP2018522860A5 true JP2018522860A5 (https=) | 2019-07-25 |
| JP6904909B2 JP6904909B2 (ja) | 2021-07-21 |
Family
ID=53784456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566712A Expired - Fee Related JP6904909B2 (ja) | 2015-06-24 | 2016-06-24 | 非晶質の金属有機構造体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11083795B2 (https=) |
| EP (1) | EP3313856A1 (https=) |
| JP (1) | JP6904909B2 (https=) |
| CN (1) | CN107771084A (https=) |
| GB (1) | GB201511125D0 (https=) |
| WO (1) | WO2016207397A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736967B2 (en) | 2016-01-05 | 2020-08-11 | Panaceanano, Inc. | Method of preparing cyclodextrin complexes |
| US10583147B2 (en) * | 2016-03-24 | 2020-03-10 | Panaceanano, Inc. | Compositions containing cyclodextrin-based metal organic frameworks |
| WO2018044874A1 (en) * | 2016-08-29 | 2018-03-08 | Cornell University | Metal organic frameworks and methods of making and using same |
| GB201717975D0 (en) * | 2017-10-31 | 2017-12-13 | Cambridge Entpr Ltd | Metal organic framework-based compositions and uses thereof |
| CN108456241A (zh) * | 2018-01-17 | 2018-08-28 | 南开大学 | 多孔框架材料用于生物制品的储运和制备 |
| WO2019173571A1 (en) * | 2018-03-09 | 2019-09-12 | Northwestern University | Insulin-loaded metal-organic frameworks |
| KR102125431B1 (ko) * | 2018-10-12 | 2020-06-23 | 한국과학기술연구원 | 크기가 조절된 UiO-66의 제조방법 및 이에 따라 제조된 활성이 향상된 화학작용제 가수분해 촉매 |
| US20210386055A1 (en) * | 2018-10-30 | 2021-12-16 | Unm Rainforest Innovations | Metal-organic Framework-Assisted Cryopreservation of Red Blood-Cells |
| WO2021035010A1 (en) * | 2019-08-20 | 2021-02-25 | Shengqian Ma | Corrole-based frameworks and methods of use thereof |
| GB201917388D0 (en) * | 2019-11-28 | 2020-01-15 | Cambridge Entpr Ltd | Novel linker compounds |
| KR102253318B1 (ko) * | 2020-06-02 | 2021-05-18 | (주)위바이오트리 | 금속 상 변환 화합물 및 이의 제조 방법 |
| CN112500581B (zh) * | 2020-12-08 | 2022-01-28 | 广西民族师范学院 | 一种基于1,3,5-三(甲氧基羧基)苯构筑的镍金属配位聚合物及其合成方法 |
| EP4011365A1 (en) | 2020-12-09 | 2022-06-15 | Cambridge Enterprise, Ltd. | Mof nanoparticles |
| CN113398956B (zh) * | 2021-06-17 | 2023-08-04 | 西安石油大学 | 一种可见光响应的BiOI光催化剂及其制备方法和应用 |
| CN113791058B (zh) * | 2021-09-15 | 2022-09-23 | 南京大学 | 一种利用lmof组成的传感器阵列检测抗生素的方法 |
| CN114657600B (zh) * | 2022-04-25 | 2023-05-19 | 江西师范大学 | 一种3D微米花复合材料Fe-CoP@C及其制备方法和应用 |
| US20250351820A1 (en) * | 2022-06-06 | 2025-11-20 | Kansas State University Research Foundation | Supramolecular porous organic frameworks for storage and delivery of volatile guests |
| CN115785468A (zh) * | 2022-11-21 | 2023-03-14 | 苏州大学 | 一种用于富集细胞外囊泡的zif-8-dspe材料及其制备方法和应用 |
| CN116584480B (zh) * | 2023-04-26 | 2025-05-23 | 南京大学 | 金属有机框架纳米农药控释剂的制备方法及其应用 |
| CN119371711B (zh) * | 2024-10-30 | 2025-06-24 | 江南大学 | 一种非晶共轭配位聚合物气凝胶材料及其制备方法与应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6024789B2 (ja) * | 1976-09-03 | 1985-06-14 | 小野薬品工業株式会社 | ５−フルオロウラシル誘導体化合物 |
-
2015
- 2015-06-24 GB GBGB1511125.5A patent/GB201511125D0/en not_active Ceased
-
2016
- 2016-06-24 CN CN201680035888.XA patent/CN107771084A/zh active Pending
- 2016-06-24 WO PCT/EP2016/064746 patent/WO2016207397A1/en not_active Ceased
- 2016-06-24 US US15/735,145 patent/US11083795B2/en not_active Expired - Fee Related
- 2016-06-24 EP EP16732291.6A patent/EP3313856A1/en not_active Withdrawn
- 2016-06-24 JP JP2017566712A patent/JP6904909B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522860A5 (https=) | ||
| IL251413B1 (en) | Composition of injectable buprenorphine | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016106150A5 (https=) | ||
| EP4467182A3 (en) | Electromechanical ingestible device for delivery of a dispensable substance | |
| RU2013113222A (ru) | Способы лечения или профилактики тромбообразования или эмболии | |
| WO2018022815A3 (en) | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug | |
| CN109311832A (zh) | 沃替西汀的帕莫酸盐及其晶型 | |
| ES2536460T3 (es) | Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| FI3360575T3 (fi) | Ihon kautta annosteltavat farmaseuttiset koostumukset, jotka käsittävät vaikuttavia aineita | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| JP2013542247A5 (https=) | ||
| BRPI0512177A (pt) | formulação de liberação modificada de memantina | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| JP2016503058A5 (https=) | ||
| JP2013537915A5 (https=) | ||
| JP2013508289A5 (https=) | ||
| JP2011507838A5 (https=) | ||
| HRP20210068T1 (hr) | Opioidne formulacije | |
| NZ591204A (en) | Pharmaceutical compositions and methods for stabilizing the same | |
| WO2007118131A3 (en) | Methods and devices for reducing tissue damage after ischemic injury | |
| WO2014203137A3 (en) | Pharmaceutical compositions of tamsulosin or salts thereof | |
| EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy |